AIDS drugs lurch towards market.
Steele
F
F
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D017277:Drug Approval; D016333:HIV Protease / Q000187:drug effects*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology*; D006801:Humans; D019469:Indinavir; D007546:Isoquinolines / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D019438:Ritonavir; D019258:Saquinavir; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011804:Quinolines; D013844:Thiazoles; D019469:Indinavir; D016333:HIV Protease; D014633:Valine; D019258:Saquinavir; D019438:Ritonavir